Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer

Shuying Liu, Xiaolong Meng, Huiqin Chen, Wenbin Liu, Todd Miller, Mandi Murph, Yiling Lu, Fan Zhang, Mihai Gagea, Carlos L. Arteaga, Gordon Mills, Funda Meric-Bernstam, Ana M. González-Angulo

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Despite numerous therapies that effectively inhibit estrogen signaling in breast cancer, a significant proportion of patients with estrogen receptor (ER)-positive malignancy will succumb to their disease. Herein we demonstrate that long-term estrogen deprivation (LTED) therapy among ER-positive breast cancer cells results in the adaptive increase in ER expression and subsequent activation of multiple tyrosine kinases. Combination therapy with the ER down-regulator fulvestrant and dasatinib, a broad kinase inhibitor, exhibits synergistic activity against LTED cells, by reduction of cell proliferation, cell survival, cell invasion and mammary acinar formation. Screening kinase phosphorylation using protein arrays and functional proteomic analysis demonstrates that the combination of fulvestrant and dasatinib inhibits multiple tyrosine kinases and cancer-related pathways that are constitutively activated in LTED cells. Because LTED cells display increased insulin receptor (InsR)/insulin-like growth factor 1 receptor (IGF-1R) signaling, we added an ant-IGF-1 antibody to the combination with fulvestrant and dasatinib in an effort to further increase the inhibition. However, adding MK0646 only modestly increased the inhibition of cell growth in monolayer culture, but neither suppressed acinar formation nor inhibited cell migration in vitro and invasion in vivo. Therefore, combinations of fulvestrant and dasatinib, but not MK0646, may benefit patients with tyrosine-kinase-activated, endocrine therapy-resistant breast cancer.

Original languageEnglish (US)
Pages (from-to)9049-9064
Number of pages16
JournalOncotarget
Volume5
Issue number19
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Receptor Protein-Tyrosine Kinases
Estrogen Receptors
Breast Neoplasms
Estrogens
Protein-Tyrosine Kinases
Phosphotransferases
Therapeutics
Somatomedin Receptors
Protein Array Analysis
Ants
Insulin Receptor
Insulin-Like Growth Factor I
Proteomics
Cell Movement
Neoplasms
Cell Survival
Breast
Phosphorylation
Cell Proliferation
fulvestrant

Keywords

  • Breast cancer
  • Dasatinib
  • Fulvestrant
  • MK0646
  • Targeting therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Liu, S., Meng, X., Chen, H., Liu, W., Miller, T., Murph, M., ... González-Angulo, A. M. (2014). Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget, 5(19), 9049-9064. https://doi.org/10.18632/oncotarget.2022

Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. / Liu, Shuying; Meng, Xiaolong; Chen, Huiqin; Liu, Wenbin; Miller, Todd; Murph, Mandi; Lu, Yiling; Zhang, Fan; Gagea, Mihai; Arteaga, Carlos L.; Mills, Gordon; Meric-Bernstam, Funda; González-Angulo, Ana M.

In: Oncotarget, Vol. 5, No. 19, 01.01.2014, p. 9049-9064.

Research output: Contribution to journalArticle

Liu, S, Meng, X, Chen, H, Liu, W, Miller, T, Murph, M, Lu, Y, Zhang, F, Gagea, M, Arteaga, CL, Mills, G, Meric-Bernstam, F & González-Angulo, AM 2014, 'Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer', Oncotarget, vol. 5, no. 19, pp. 9049-9064. https://doi.org/10.18632/oncotarget.2022
Liu, Shuying ; Meng, Xiaolong ; Chen, Huiqin ; Liu, Wenbin ; Miller, Todd ; Murph, Mandi ; Lu, Yiling ; Zhang, Fan ; Gagea, Mihai ; Arteaga, Carlos L. ; Mills, Gordon ; Meric-Bernstam, Funda ; González-Angulo, Ana M. / Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. In: Oncotarget. 2014 ; Vol. 5, No. 19. pp. 9049-9064.
@article{4142fa694da84e79b2ab4c5a28532f97,
title = "Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer",
abstract = "Despite numerous therapies that effectively inhibit estrogen signaling in breast cancer, a significant proportion of patients with estrogen receptor (ER)-positive malignancy will succumb to their disease. Herein we demonstrate that long-term estrogen deprivation (LTED) therapy among ER-positive breast cancer cells results in the adaptive increase in ER expression and subsequent activation of multiple tyrosine kinases. Combination therapy with the ER down-regulator fulvestrant and dasatinib, a broad kinase inhibitor, exhibits synergistic activity against LTED cells, by reduction of cell proliferation, cell survival, cell invasion and mammary acinar formation. Screening kinase phosphorylation using protein arrays and functional proteomic analysis demonstrates that the combination of fulvestrant and dasatinib inhibits multiple tyrosine kinases and cancer-related pathways that are constitutively activated in LTED cells. Because LTED cells display increased insulin receptor (InsR)/insulin-like growth factor 1 receptor (IGF-1R) signaling, we added an ant-IGF-1 antibody to the combination with fulvestrant and dasatinib in an effort to further increase the inhibition. However, adding MK0646 only modestly increased the inhibition of cell growth in monolayer culture, but neither suppressed acinar formation nor inhibited cell migration in vitro and invasion in vivo. Therefore, combinations of fulvestrant and dasatinib, but not MK0646, may benefit patients with tyrosine-kinase-activated, endocrine therapy-resistant breast cancer.",
keywords = "Breast cancer, Dasatinib, Fulvestrant, MK0646, Targeting therapy",
author = "Shuying Liu and Xiaolong Meng and Huiqin Chen and Wenbin Liu and Todd Miller and Mandi Murph and Yiling Lu and Fan Zhang and Mihai Gagea and Arteaga, {Carlos L.} and Gordon Mills and Funda Meric-Bernstam and Gonz{\'a}lez-Angulo, {Ana M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.18632/oncotarget.2022",
language = "English (US)",
volume = "5",
pages = "9049--9064",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "19",

}

TY - JOUR

T1 - Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer

AU - Liu, Shuying

AU - Meng, Xiaolong

AU - Chen, Huiqin

AU - Liu, Wenbin

AU - Miller, Todd

AU - Murph, Mandi

AU - Lu, Yiling

AU - Zhang, Fan

AU - Gagea, Mihai

AU - Arteaga, Carlos L.

AU - Mills, Gordon

AU - Meric-Bernstam, Funda

AU - González-Angulo, Ana M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Despite numerous therapies that effectively inhibit estrogen signaling in breast cancer, a significant proportion of patients with estrogen receptor (ER)-positive malignancy will succumb to their disease. Herein we demonstrate that long-term estrogen deprivation (LTED) therapy among ER-positive breast cancer cells results in the adaptive increase in ER expression and subsequent activation of multiple tyrosine kinases. Combination therapy with the ER down-regulator fulvestrant and dasatinib, a broad kinase inhibitor, exhibits synergistic activity against LTED cells, by reduction of cell proliferation, cell survival, cell invasion and mammary acinar formation. Screening kinase phosphorylation using protein arrays and functional proteomic analysis demonstrates that the combination of fulvestrant and dasatinib inhibits multiple tyrosine kinases and cancer-related pathways that are constitutively activated in LTED cells. Because LTED cells display increased insulin receptor (InsR)/insulin-like growth factor 1 receptor (IGF-1R) signaling, we added an ant-IGF-1 antibody to the combination with fulvestrant and dasatinib in an effort to further increase the inhibition. However, adding MK0646 only modestly increased the inhibition of cell growth in monolayer culture, but neither suppressed acinar formation nor inhibited cell migration in vitro and invasion in vivo. Therefore, combinations of fulvestrant and dasatinib, but not MK0646, may benefit patients with tyrosine-kinase-activated, endocrine therapy-resistant breast cancer.

AB - Despite numerous therapies that effectively inhibit estrogen signaling in breast cancer, a significant proportion of patients with estrogen receptor (ER)-positive malignancy will succumb to their disease. Herein we demonstrate that long-term estrogen deprivation (LTED) therapy among ER-positive breast cancer cells results in the adaptive increase in ER expression and subsequent activation of multiple tyrosine kinases. Combination therapy with the ER down-regulator fulvestrant and dasatinib, a broad kinase inhibitor, exhibits synergistic activity against LTED cells, by reduction of cell proliferation, cell survival, cell invasion and mammary acinar formation. Screening kinase phosphorylation using protein arrays and functional proteomic analysis demonstrates that the combination of fulvestrant and dasatinib inhibits multiple tyrosine kinases and cancer-related pathways that are constitutively activated in LTED cells. Because LTED cells display increased insulin receptor (InsR)/insulin-like growth factor 1 receptor (IGF-1R) signaling, we added an ant-IGF-1 antibody to the combination with fulvestrant and dasatinib in an effort to further increase the inhibition. However, adding MK0646 only modestly increased the inhibition of cell growth in monolayer culture, but neither suppressed acinar formation nor inhibited cell migration in vitro and invasion in vivo. Therefore, combinations of fulvestrant and dasatinib, but not MK0646, may benefit patients with tyrosine-kinase-activated, endocrine therapy-resistant breast cancer.

KW - Breast cancer

KW - Dasatinib

KW - Fulvestrant

KW - MK0646

KW - Targeting therapy

UR - http://www.scopus.com/inward/record.url?scp=84910029848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910029848&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.2022

DO - 10.18632/oncotarget.2022

M3 - Article

VL - 5

SP - 9049

EP - 9064

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 19

ER -